Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
2.
Cancer care crowdfunding increasingly common, but rarely successful
3.
Novel radiotracer identifies biomarker for triple-negative breast cancer
4.
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer
5.
June 20, 2023, Health Bulletin No. 12.
1.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
2.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
5.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge